Alteplase

Generic Name
Alteplase
Brand Names
Activase, Cathflo, Cathflo Activase
Drug Type
Biotech
Chemical Formula
-
CAS Number
105857-23-6
Unique Ingredient Identifier
1RXS4UE564
Background

Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin. Alteplase is a purified gl...

Indication

Alteplase is indicated for the treatment of acute ischemic stroke (AIS) and for use in acute myocardial infarction (AMI) for the reduction of mortality and incidence of heart failure. Alteplase is also indicated for the lysis of acute massive pulmonary embolism, defined as acute pulmonary emboli obstructing blood flow to a lobe or multiple lung segments, and...

Associated Conditions
Acute Ischemic Stroke, Cardiac mortality, Heart Failure, Pulmonary Embolism Acute Massive, Central venous access device thrombosis
Associated Therapies
-
Clinical Trials
Related News

Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization

Completed
Conditions
Stroke
Interventions
Drug: rt-PA
First Posted Date
2022-05-27
Last Posted Date
2024-12-20
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
113035
Registration Number
NCT05395351
Locations
🇨🇳

Boehringer Ingelheim (China) Investment Co., ltd., Shanghai, China

Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-II）

First Posted Date
2022-03-16
Last Posted Date
2022-03-31
Lead Sponsor
Beijing Tiantan Hospital
Target Recruit Count
225
Registration Number
NCT05281549
Locations
🇨🇳

Huai'an Second People's Hospital, Huai'an, Jiangsu, China

🇨🇳

Tangshan Gongren Hospital, Tangshan, Hebei, China

🇨🇳

Mei He Kou Central Hospital, Meihekou, Jilin, China

and more 25 locations

Early Reperfusion Therapy With Intravenous Alteplase for Recovery of VISION in Acute Central Retinal Artery Occlusion

Phase 3
Recruiting
Conditions
Central Retinal Artery Occlusion
Interventions
Drug: Alteplase
First Posted Date
2021-07-16
Last Posted Date
2024-05-08
Lead Sponsor
University Hospital Tuebingen
Target Recruit Count
422
Registration Number
NCT04965038
Locations
🇩🇪

University Hospital Tuebingen, Tuebingen, Germany

In Situ Thrombolysis With tPA and Inflow Perfusion Analysis in Patient With Severe Covid-19 Infection

Not Applicable
Completed
Conditions
COVID-19
Interventions
Drug: tPA
First Posted Date
2021-06-15
Last Posted Date
2021-06-21
Lead Sponsor
Grupo Mexicano para el Estudio de la Medicina Intensiva
Target Recruit Count
15
Registration Number
NCT04926428
Locations
🇲🇽

Hospital General de Mexico Dr Eduardo Liceaga, Mexico City, Mexico

A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity

Phase 3
Completed
Conditions
Stroke
Interventions
Drug: tenecteplase
Drug: alteplase
First Posted Date
2021-06-07
Last Posted Date
2024-12-10
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1489
Registration Number
NCT04915729
Locations
🇨🇳

Inner Mongolia Baogang Hospital, Baotou, China

🇨🇳

Beijing Chao-Yang Hospital, Beijing, China

🇨🇳

Beijing Tsinghua Changgung Hospital, Beijing, China

and more 52 locations

24 Hours Treatment With Alteplase in Patients With Ischemic Stroke

Phase 3
Recruiting
Conditions
Stroke
Interventions
Drug: Alteplase
First Posted Date
2021-05-10
Last Posted Date
2023-02-06
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
372
Registration Number
NCT04879615
Locations
🇨🇳

Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China

Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis

First Posted Date
2021-03-19
Last Posted Date
2024-12-11
Lead Sponsor
Memorial Healthcare System
Target Recruit Count
27
Registration Number
NCT04806373
Locations
🇺🇸

Memorial Healthcare System, Hollywood, Florida, United States

Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ

Phase 3
Completed
Conditions
Acute Ischemic Stroke
Interventions
Drug: rhTNK-tPA
Drug: rt-PA
First Posted Date
2021-03-15
Last Posted Date
2023-01-17
Lead Sponsor
Beijing Tiantan Hospital
Target Recruit Count
1430
Registration Number
NCT04797013
Locations
🇨🇳

The first affiliated hospital of ustc, Hefei, Anhui, China

🇨🇳

The people's hospltal of xuancheng city, Xuancheng, Anhui, China

🇨🇳

Beijing luhe hospital capital medical university, Beijing, Beijing, China

and more 58 locations

Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPE

First Posted Date
2020-12-29
Last Posted Date
2023-08-04
Lead Sponsor
Supergene, LLC
Target Recruit Count
310
Registration Number
NCT04688320
Locations
🇷🇺

Sergiyev Posad Regional Clinical Hospital, Sergiyev Posad, Moscow Region, Russian Federation

🇷🇺

V.F. Dolgopolov Vyselki Central District Hospital, Vyselki, Krasnodar Region, Russian Federation

🇷🇺

Krasnoyarsk Regional Clinical Hospital, Krasnoyarsk, Russian Federation

and more 20 locations

Anxiety and Depression Disorder in Patient Treated With rTPA for Mangment of Acute Ischemic Stroke

First Posted Date
2020-07-23
Last Posted Date
2020-07-23
Lead Sponsor
Assiut University
Target Recruit Count
40
Registration Number
NCT04484558
Locations
🇪🇬

Assiut university, Assiut, Egypt

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy